Özet:

Purpose: to evaluate the effectiveness and reliability of the combined intravitreal (IV) triamsinolone acetonide (TA) and IV bevacizumab (IVB) treatment in the short term in the macula infection associated with retinal venic obstruction (RVT). Tools and Methods: In this backward study, a total of 20 patients, including 5 (25%) patients with a diagnosis of central retinal venous inhibition (SRVT) and 15 (75%) patients with a diagnosis of retinal venous inhibition (RVDT), were included. Patients were given a combined IVTA (2 mg, 0.05 ml)-IVB (1,25 mg, 0.05 ml) injection. Patients had a corrected visual sharpness (DGK), intraocular pressure (GIB) and central macula thickness (SMK) examination. Results: Patients[E/K=11/9, average age 66.35 ± 6,002 years (medium ± standard deviation)] combined IVTA-IVB injection pre-SMK value 526.85 ± 69.20 microns, combined injection treatment 1 month after SMK value 350,65 ± 44,01 microns, 3 months after SMK value 398.65 ± 58.97 microns were found. The DGK prior to combined IVTA-IVB injection value was 1.43 ± 0.66 Log Mar, the DGK value 1 month after combined injection treatment was 1.025 ± 0.61 Log Mar, and the DGK value 3 months later was 1.18 ± 0.66 Log Mar. The average SMK and DGK values significantly decreased in the 1st month after treatment (secondly; p=0,001, p=0,018) and in the 3rd month (secondly; p=0,001, p=0,029) compared to before treatment. The result: Combined IVTA-IVB treatment in RVT-related macula is effective and reliable in a short period of time. Short term effect of combined intravitreal triamcinolone acetonid-bevacizumab treatment in retinal vein occlusion. ABSTRACT Objective: To evaluate safety and effectiveness of combined intravitreal (IV) triamcinolone acetonide (TA) and IV bevacizumab (IVB) treatment in macular edema due to retinal vein occlusion in short term. Material and Methods: In this retrospective study, 20 eyes of the 20 patients with macular edema due to retinal vein occlusion 5 (25%) patients with central retinal vein occlusion and 15 (75%) patients with branch retinal vein occlusion) were included. Patients received combined IVTA (2 mg, 0, 05 ml) and IVB (1, 25 mg, 0, 05 ml) injection. Complete ocular examinations including corrected visual acuity (CVA), intraocular pressure (IOP), and central macular thickness (CMT) were performed. Results: The average age of the patients (Male/Female= 11/9) was 66, 35 ± 6,002 years (mean ± standard deviation). Before combined IVTA-IVB treatment, CMT was 526.85 ± 69.20 micron. One month after combined IVTA-IVB treatment CMT was 350,65 ± 44,01 micron and 3 months after treatment CMT was 398,65 ± 58,97 micron. Before combined IVTA-IVB treatment, CVA was 1.43 ± 0.66 Log Mar. One month after combined IVTA-IVB treatment CVA was 1,025 ± 0, 61 Log Mar and 3 months after treatment CVA was 1,18 ± 0,66 Log Mar. Both CMT and CVA (in turn) base-line values decreased significantly 1 month (p=0,001, p=0,018) and 3 months (p=0,001, p=0,029) following the treatment. Conclusion: Combined IVTA-IVB treatment in macular edema due to retinal vein occlusion is safe and effective in short term. Key words: bevacizumab ; Retinal Vein Occlusion ; Triamcinolone